Astrazeneca (AZN) Total Liabilities (2009 - 2026)
Astrazeneca (AZN) posted quarterly Total Liabilities of $65.5 billion for Q2 2026, down 3.18% year-over-year from $67.6 billion in Q2 2025, and up 198.25% quarter-over-quarter from -$66.6 billion in Q1 2026.
Astrazeneca (AZN) Total Liabilities (2009 - 2026) Analysis & Trends
Astrazeneca's Total Liabilities history runs 18 years deep, the most recent figure standing at $65.5 billion for Q2 2026.
- In Q2 2026, Total Liabilities fell 3.18% year-over-year to $65.5 billion; the TTM figure through Jun 2026 stood at $65.5 billion (down 3.18% YoY), while the FY2025 annual figure was $65.4 billion, up 3.47% from the prior year.
- Total Liabilities for Q2 2026 stood at $65.5 billion, up from -$66.6 billion in the prior quarter.
- The five-year high for Total Liabilities was $67.6 billion in Q2 2025, with the low at -$68.5 billion in Q3 2025.
- The 5-year median for Total Liabilities is -$59.9 billion (2022), against an average of -$20.7 billion.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities slumped 60.25% in 2022, then jumped 204.43% in 2025.
- Astrazeneca's Total Liabilities stood at $59.4 billion in 2022, then climbed by 4.25% to $62.0 billion in 2023, then advanced by 1.95% to $63.2 billion in 2024, then gained by 3.47% to $65.4 billion in 2025, then gained by 0.17% to $65.5 billion in 2026.
- Business Quant data shows AZN's Total Liabilities at $65.5 billion in Q2 2026, -$66.6 billion in Q1 2026, and $65.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.61 Bn | 630.85 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 470.09 Bn | 463.53 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 374.19 Bn | 367.05 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 302.72 Bn | 295.03 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.19 Bn | 252.29 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 236.77 Bn | 222.78 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 182.67 Bn | 179.49 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.97 Bn | 101.81 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 55.16 Bn | 47.78 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.46 Bn |
| Mar 31, 2026 | -66.63 Bn |
| Dec 31, 2025 | 65.36 Bn |
| Sep 30, 2025 | -68.49 Bn |
| Jun 30, 2025 | 67.61 Bn |
| Mar 31, 2025 | -65.12 Bn |
| Dec 31, 2024 | 63.16 Bn |
| Sep 30, 2024 | -64.12 Bn |
| Jun 30, 2024 | -64.74 Bn |
| Mar 31, 2024 | -64.79 Bn |
| Dec 31, 2023 | 61.95 Bn |
| Sep 30, 2023 | -58.87 Bn |
| Jun 30, 2023 | -59.13 Bn |
| Mar 31, 2023 | -60.88 Bn |
| Dec 31, 2022 | 59.43 Bn |
| Sep 30, 2022 | -59.03 Bn |
| Jun 30, 2022 | -60.63 Bn |
| Mar 31, 2022 | -63.91 Bn |
| Dec 31, 2021 | 66.08 Bn |
| Sep 30, 2021 | -67.31 Bn |